Positive News SentimentPositive NewsNASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis $1.33 -0.05 (-3.61%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About InterCure Stock (NASDAQ:INCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InterCure alerts:Sign Up Key Stats Today's Range$1.32▼$1.4050-Day Range$1.17▼$2.0152-Week Range$1.10▼$3.72Volume34,509 shsAverage Volume54,458 shsMarket Capitalization$60.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More… “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. InterCure Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks25th Percentile Overall ScoreINCR MarketRank™: InterCure scored higher than 25% of companies evaluated by MarketBeat, and ranked 861st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InterCure. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioInterCure has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently decreased by 21.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterCure does not currently pay a dividend.Dividend GrowthInterCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently decreased by 21.91%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentInterCure has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for InterCure this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InterCure insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 8.34% of the stock of InterCure is held by institutions.Read more about InterCure's insider trading history. Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address INCR Stock News HeadlinesRising High: Exclusive talk with house of brands Carma HoldCoNovember 7, 2024 | markets.businessinsider.comInterCure Ltd. (INCR)October 16, 2024 | finance.yahoo.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 21, 2024 | Crypto Swap Profits (Ad)Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed CompanySeptember 14, 2024 | benzinga.comInterCure partners with Cookies to launch cannabis pharmacies in GermanyAugust 30, 2024 | investing.comTop Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On GermanyAugust 30, 2024 | msn.comInterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 30, 2024 | finanznachrichten.deInterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 29, 2024 | globenewswire.comSee More Headlines INCR Stock Analysis - Frequently Asked Questions How have INCR shares performed this year? InterCure's stock was trading at $1.2898 at the beginning of 2024. Since then, INCR shares have increased by 3.4% and is now trading at $1.3339. View the best growth stocks for 2024 here. Who are InterCure's major shareholders? Top institutional shareholders of InterCure include Jane Street Group LLC (0.06%) and Virtu Financial LLC (0.05%). How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of InterCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV). Company Calendar Today11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INCR CUSIPN/A CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.15 Current Ratio1.78 Quick Ratio1.15 Sales & Book Value Annual Sales$272.67 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.72 per share Price / Book0.49Miscellaneous Outstanding Shares45,573,000Free FloatN/AMarket Cap$60.79 million OptionableOptionable Beta1.52 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:INCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.